Form 4: CalciMedica CEO Acquires 285,000 Employee Stock Options

Rachel A. Leheny, CEO of CalciMedica, Inc., reports the acquisition of 285,000 employee stock options.

Summary

• Rachel A. Leheny, the CEO of CalciMedica, Inc., filed a Form 4 on April 25, 2025, reporting a transaction.
• The transaction involved the acquisition of 285,000 employee stock options with an exercise price of $1.53.
• These options were granted on April 23, 2025, and vest monthly starting March 26, 2025, over a four-year period, expiring on April 22, 2035.
• Following the transaction, Leheny directly owns 285,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule of four years with monthly installments is a standard practice to incentivize long-term commitment.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as the CEO's confidence in the company.

Key Dates

Keywords

CalciMedica, Stock Options, Form 4, SEC Filing, Insider Transaction, Leheny, CEO